COMMUNIQUÉS West-GlobeNewswire

Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096
02/06/2026
FDA considered the planned HER-096 Phase 2a study design appropriate Study design finalized; approximately 100 patients to be enrolled More than 50% of Phase 2 funding secured or identified Espoo, Finland, 2 June 2026: [...]
Ocugen to Participate in Upcoming June Investor and Industry Conferences
02/06/2026
MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will [...]
Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096
02/06/2026
FDA considered the planned HER-096 Phase 2a study design appropriate Study design finalized; approximately 100 patients to be enrolled More than 50% of Phase 2 funding secured or identified Espoo, Finland, 2 June 2026: [...]
Lifecore Biomedical Signs Agreement with New Biopharmaceutical Customer
02/06/2026
-- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Injectable Ophthalmic Product -- -- Sixth Addition to Late-Stage Pipeline in Seven Months -- CHASKA, Minn., June 02, 2026 ( [...]
Ocular Therapeutix™ to Host Investor Day on June 17, 2026
02/06/2026
In addition to Ocular leadership, event to feature prominent retinal disease experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Lejla Vajzovic, MD, FASRS; and Dr. Darius M. Moshfeghi, MD Company to highlight AXPAXLI™ wet [...]
Integra LifeSciences to Present at the 2026 Jefferies Global Healthcare Conference
02/06/2026
PRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief financial officer Lea Knight will [...]
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
02/06/2026
Study now 50% enrolled 6 of 8 participants have already met the responder criterion for the study’s primary endpoint Topline results for the fully enrolled open-label study are expected in the second half of 2026 [...]
FDA Grants Fast Track Designation to Merakris’ MTX-001, Opening Potential Accelerated Path to Market for Venous Leg Ulcer Therapy
02/06/2026
Fast Track Designation Provides Opportunities for Rolling BLA Review, Enhanced FDA Engagement, and Earlier Alignment on Manufacturing and Regulatory Requirements RESEARCH TRIANGLE PARK, N.C., June 02, 2026 (GLOBE [...]
CorVel Marks 35 Years on Nasdaq, Signals Next Phase of Long-Term Innovation and Growth
02/06/2026
FORT WORTH, Texas, June 02, 2026 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL) today announced that it will mark its 35th anniversary as a publicly traded company listed on the Nasdaq Stock Market. Members of [...]
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
02/06/2026
Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN) Revised ORIGIN 3 eGFR analysis now [...]
Lumexa Imaging Announces Joint Venture with Hospital for Special Surgery (HSS) to Expand Advanced Outpatient Imaging in New York
02/06/2026
This collaboration marks Lumexa Imaging’s ninth joint venture and advances the company’s health system growth strategy RALEIGH, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (NASDAQ: LMRI), one of the nation’s [...]
Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism
02/06/2026
Growing momentum for RAS inhibition at ASCO highlights Namodenoson’s RAS pathway inhibition and encouraging data in pancreatic cancer Ramat Gan, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE [...]
Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts
02/06/2026
RESEARCH TRIANGLE PARK, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore [...]
Picard Medical / SynCardia Advances Emperor Total Artificial Heart Program with Successful Next-Generation Preclinical Implant Studies
02/06/2026
— Independent dual motor ventricular design demonstrates stable full circulatory support across all study procedures — — Advancing second-generation Emperor TAH development toward a fully implantable system — TUCSON, [...]
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
02/06/2026
Orphan Drug Designation is intended to support the development of therapies for rare diseases affecting fewer than 200,000 people in the United States MIAMI, June 02, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp [...]
The Ensign Group Acquires Real Estate and Operations in Iowa
02/06/2026
SAN JUAN CAPISTRANO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
SEED Therapeutics Highlights Clinical Advancement and Broad Oncology Potential of ST-01156, an RBM39 Molecular Glue Degrader in First-in-Human in Phase 1 Studies, at ASCO 2026
02/06/2026
Oral, Selective RBM39 Degrader Under Evaluation in Phase 1 Trial; Preclinical Data Support Expansion Potential Across Ewing Sarcoma, Hepatocellular Carcinoma, KRAS-Mutant Cancers, Neuroblastoma, and Other RBM39- [...]
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia
02/06/2026
Optimi’s 5mg psilocybin capsules are prescribed commercially for treatment-resistant depression in Australia, with additional product from the run earmarked for planned clinical trials in the United States and Europe [...]
The Ensign Group Purchases Memory Care Facility in California
02/06/2026
SAN JUAN CAPISTRANO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior living [...]

Pages